Avieum Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.40 M
- Paid Up Capital ₹ 0.32 M
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 2.75 Cr
- Revenue Growth 544.72%
- Profit Growth -34.58%
- Ebitda -16.40%
- Net Worth 156.31%
- Total Assets 74.64%
About Avieum Life Sciences
Avieum Life Sciences Private Limited (ALSPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 11 January 2017 (Eight years and one month 10 days old ). Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.40 M and a paid-up capital of Rs 0.32 M.
The company currently has active open charges totaling ₹2.75 Cr.
Ramesh Kale, Vanita Kale, Sanjay Chandake, and One other member serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U73100PN2017PTC167898
- Company No.
167898
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jan 2017
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Avieum Life Sciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Chandake  | Director | 20-Jan-2018 | Current |
| Ramesh Kale | Director | 11-Jan-2017 | Current |
| Vanita Kale | Director | 11-Jan-2017 | Current |
| Ravindra Wakchaure | Director | 26-Dec-2019 | Current |
Financial Performance of Avieum Life Sciences.
Avieum Life Sciences Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 544.72% increase. The company also saw a substantial fall in profitability, with a 34.58% decrease in profit. The company's net worth Soared by an impressive increase of 156.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Avieum Life Sciences?
In 2019, Avieum Life Sciences had a promoter holding of 64.57% and a public holding of 35.43%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹27.50 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of India : 2.75 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Nov 2017 | Bank Of India | ₹2.75 Cr | Open |
How Many Employees Work at Avieum Life Sciences?
Avieum Life Sciences has a workforce of 49 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avieum Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avieum Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
